The two new additions to the board of directors, Dr. Caroline MacCallum and Jacques Dessurealt respectively, provide scientific and medical credentials as well as strategic expertise and direction with years of proven experience in both the academic and corporate spheres of influence.
MacCallum’s CV includes her roles as an internist, complex and cannabinoid clinician, researcher, and clinical instructor in the department of medicine. She’s also an adjunct professor in the pharmaceutical sciences faculty, and an associate member of the palliative care department at the University of British Columbia.
She also serves as the medical director at Greenleaf Medical Clinic, where her accomplishments and duties include the assessment and development of cannabinoid treatment plans for more than 3,000 patients Canada-wide.
Her most recent publication, called “Practical Consideration for Medical Cannabis Administration and Dosing,” has the honour of being the first of its kind on medical cannabis dosing. She has presented internationally on cannabis initiatives and is a recognized expert regarding several medical cannabis courses.
Her endeavours include working with university research groups, hospitals, health benefit programs and both provincial and national committees for the construction of cannabis guidelines for use in clinical trials, safe prescribing practices and patient registries. She has also studied and remains focused on the notion of cannabis as a substitute for opioid use.
“Dr. MacCallum’s vast experience in cannabinoid research will be invaluable to TGOD. She has been recognized by her peers in the medical industry as an expert in medical cannabis with a focus on dosing, which will be critical as we prepare to launch a suite of multidose products under the recently announced Responsible Regulation of Edible Cannabis Products in Canada,” said Brian Althaide, CEO and director of TGOD.
In many ways, TGOD’s second addition to their board of directors, Jacques Dessurealt, acts as an unusual contrast to MacCallum’s straight-forward medical and scientific credentials.
While he’s not exactly shy on scientific credentials himself, having enjoyed an extensive pharmaceutical career, he’s branched off by serving at Novartis (NUS.Z), a global marketing division based in Basel, Switzerland. He’s also served in domestic senior executive roles as both president and general manager of Valeant Pharmaceutical, now Bausch Health (BHC.T), as well as VP of Bristol Myer-Squibb (BMY.Z), and then serving as general manager for Novartis Canada.
While working for Valeant, Dessureault oversaw the company’s research and development, international manufacturing and technical operations in Canada.
“Mr. Dessureault’s senior executive and entrepreneurial experience in growing businesses, improving efficiency, and leading research and development teams will be invaluable to TGOD. As we advance the research and development arms of our company, including our beverage science and research division, Jacques’s experience will be critical to launching new novel and innovative product lines,” Althaide said.
Beyond his exploits in the pharmaceutical sphere, Dessurealt also acts as a strategic advisor for Cirque du Soleil, as well as a board member of Optina Diagnostics, part of the management committee of The Rosalind & Morris Goodman Family Pediatric Formulations Centre of the CHU Sainte-Justine and is involved in academia with l’Ecole des Sciences de la Gestion of Universite du Quebec a Montreal.
“We are incredibly fortunate to add Dr. MacCallum and Jacques Dessureault to our board of directors at such a pivotal time, as we approach production ramp-up and our first commercial sales. The TGOD board now consists of independent directors with the exception of our CEO. Both new additions possess valuable skills and extensive experience that will greatly benefit TGOD moving forward,” said Jeff Scott, chairman of the board.
To make room for MacCallum and Dessureault, Ian Wilms has agreed to step down from the board of directors. Wilms had been a director since the company’s formation, and he will continue in his role of government affairs and compliance.
Full Disclosure: TGOD is an Equity Guru marketing client.